Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.49 |
| ▸ | CNR1 | P21554 | 4/20 | 0.47 |
| ▸ | UGCG | Q16739 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1337805 | 1.00 | CNR2 (0.49) | CNR2CNR1UGCGCYP2C9GRIA2 | |
| SCHEMBL1337553 | 0.87 | CNR2 (0.46) | CNR2CNR1UGCGCYP2C9GRIA2 | |
| SCHEMBL1337554 | 0.87 | CNR2 (0.46) | CNR2CNR1UGCGCYP2C9GRIA2 | |
| SCHEMBL12129738 | 0.86 | CNR2 (0.48) | CNR2CNR1 | |
| SCHEMBL1337790 | 0.82 | CNR2 (0.51) | CNR2CNR1UGCGGRIA2 | |
| SCHEMBL1337792 | 0.82 | CNR2 (0.51) | CNR2CNR1UGCGGRIA2 | |
| SCHEMBL1175632 | 0.75 | CNR2 (0.77) | CNR2CNR1 | |
| SCHEMBL1175630 | 0.75 | CNR2 (0.77) | CNR2CNR1 | |
| SCHEMBL1175743 | 0.73 | CNR2 (0.72) | CNR2CNR1 | |
| SCHEMBL1175744 | 0.73 | CNR2 (0.72) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391627-B1 | BICYCLIC PYRAZOLO-HETEROCYCLES | CARA THERAPEUTICS INC (US) | 2013-12-25 | — | — | EP | claimed |
| US-8653127-B2 | Bicyclic pyrazolo-heterocycles | CARA THERAPEUTICS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| EP-2391627-B1 | BICYCLIC PYRAZOLO-HETEROCYCLES | CARA THERAPEUTICS INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-20110275609-A1 | BICYCLIC PYRAZOLO-HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275609-A1 | BICYCLIC PYRAZOLO-HETEROCYCLES | CNR1, CNR2, HRH4 | CNR2 2/4885CNR1 1/4885UGCG 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.